Article
Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Biochimica et biophysica acta - 1 Mar 2013
Berge Elisabet O, Huun Johanna, Lillehaug Johan R, Lønning Per E, Knappskog Stian
Abstract excerpt
BACKGROUND: Approximately 4300 different TP53 mutations have been reported in human cancers. TP53 mutations, in particular those affecting the L2/L3 domains, are associated with resistance to anthracycline or mitomycin treatment in breast cancer patients. While many mutations have been characterised functionally, novel TP53 mutations are continuously reported. Here, we characterise 10 p53 protein variants encoded...
Topics
- Anthracyclines
- Antibiotics, Antineoplastic
- Apoptosis
- Biopsy
- Breast Neoplasms
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Drug Resistance, Neoplasm
- Female
- Gene Expression Regulation, Neoplastic